Question 1

What is the analyst consensus rating for CHRS?

Accepted Answer

The analyst consensus rating for CHRS is "Buy" based on 1 analyst recommendations.

Question 2

What is the average price target for CHRS?

Accepted Answer

The average 12-month price target for CHRS is $10.00, representing an upside of 521.1% from the current price of $1.61.

Question 3

What do analyst ratings mean?

Accepted Answer

Analyst ratings indicate investment recommendations: Strong Buy and Buy are bullish signals suggesting the stock may outperform. Hold means the stock is fairly valued. Sell and Strong Sell are bearish signals suggesting potential underperformance. These ratings are based on fundamental analysis and valuation models.

Question 4

What is a price target?

Accepted Answer

A price target is an analyst's projection of a stock's fair value over a specific timeframe, typically 12 months. Analysts use fundamental analysis, financial modeling, and industry comparisons to estimate where the stock should trade. Price targets can range from low (conservative) to high (optimistic) estimates.

Coherus Oncology (CHRS) Stock Analyst Forecast

Analyst Consensus Rating

Consensus Rating

Average Price Target

Latest CHRS Analyst Ratings & Recommendations